Proven Bleed Protection

Zero median spontaneous bleeds* regardless of dosing schedule and age

  • Shown in children, adolescents, and adults when treated with AFSTYLA as prophylaxis
  • Equal protection in clinical trials, whether dosed 2 or 3 times a week
  • Verified in the largest hemophilia A pivotal clinical trial program to date (258 participants, 226 received prophylaxis)
  • Overall annualized bleeding rate in adults and adolescents was 1.14%

How efficacy was measured in the AFSTYLA clinical trials

Annualized spontaneous bleeding rate (AsBR) describes the number of spontaneous bleeds, or bleeds that occur without an obvious cause, over a year

Annualized bleeding rate (ABR) describes the number of bleeds that occur over a year due to any cause

*AsBR in clinical trials (interquartile range [IQR]=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years). ABR in clinical trials (IQR = 0–4.2 for patients ≥12 years; 0–7.2 for patients <12 years).

Dependable bleed control when you need it

On-demand treatment

The majority of bleeds were successfully resolved with 1 infusion.

On-demand chart: bleeds were controlled with 1 to 2 infusions of AFSTYLA

Pre- and post-surgery control

100% of surgeries had excellent or good bleeding control

With AFSTYLA, surgical bleeding control was rated "excellent" in 15 surgeries and "good" in 1 surgery.

You are now leaving the current website.

Do you want to continue?

No Yes